The Path Forward
Our Composite Ocular Blood Flow Analyzer (COBFA) was originally developed by Dr. Maurice Langham, the former Director of the Johns Hopkins Wilmer Eye Institute. He passed away a few years ago, but he asked his associates Dr. Theresa Kramer and Rhonda Grebe to continue leading the research and development of the device. We believe OcuFLOW™ has the potential to significantly transform lives with adoption of our intraocular blood flow analyzer.
Theresa Kramer, MD, MBA
Founder, Chief Executive Officer & Chief Medical Officer
Board-certified as an Ophthalmologist and Ophthalmic Pathologist, Theresa served on the original development team for OcuFLOW’s predicate device which has a 20-year history in academic ophthalmology. She participated in the original development of OBF technology, publishing articles on ocular blood flow. She serves as an elected board member and committee member for national organizations including ARVO, AAO, AAOOP. As Vice Chair of Finance at the Emory Eye Center, she’s been instrumental in driving process improvements with significant financial impact across the institution. Theresa completed medical school at University of Maryland, Internship at Washington Hospital Center, Ophthalmology Residency and Ophthalmic Pathology Fellowship at the Emory Eye Center, and MBA at Emory University Goizueta Business School.
Chief Financial Officer
Tom has been engaged for more than 40 years in corporate financial controls and governance. He served as CFO for two communications technology company IPOs (NASDAQ:TSYS and DIGX), and guided their growth financing, leading to the successful sales of both companies. He served on the Board of private company Antenna Research Associates, Inc. which completed a significant liquidity event in 2018. He began his career as an auditor with Price Waterhouse, where he worked for 12 years. He is chair of the Board of the YMCA in Central Maryland and a gubernatorial appointee to the Board of Trustees of the Maryland Supplemental Retirement Plans. Tom received his MBA from the Wharton School of the University of Pennsylvania, and his Bachelor’s degree in Management Science and Economics from Duke University.
Chief Operating Officer
Stephanie has a Chemical Engineering degree from Oklahoma State University and has spent twenty years in a variety of industries including food and oil. However, the bulk of her career was in biotechnology with Amgen, Inc. Through her career, Stephanie held several staff and management positions including Distribution Center Manager, Engineering Project Manager, Maintenance Manager, and Operations Development Team Leader for several ongoing products and development through global launch of a new product. Her experiences have given her a strong background in contract management, regulatory, financial, and operational requirements.
Chief Commercial Officer
John has worked for more than twenty-five years across the industry, provider and payer segments of healthcare. He’s held leadership roles across the sales, marketing, and operations spectrum, working for Amgen, Medivation and Alexion. Commercial-facing roles at St. Luke’s Health System in Idaho and later with Idaho Medicaid served to broaden his perspective of the healthcare market. He’s consulted for several entrepreneurial startups in the healthcare technology space. John holds a BA in chemistry and an MBA from the University of Colorado. He received his Master of International Management (MIM) from the Thunderbird Graduate School of International Management.
Vice President – Development
Robin is the primary inventor of the OcuFLOW- COBFA device and co-founder of the company. He is a career entrepreneurial inventor, starting with building his own experimental aircraft, the DuBois 442 (N22AZ). His projects range from information technology in electronic health records, workflow tracking for nursing care, to the use of RFID to enhance the quality of healthcare.
Rhonda has 43 years experience researching ocular blood flow and how it relates to various disease states in the eye and 20 years as part of the Langham team in developing and testing the original ocular blood flow system. She has worked as a Sr. Research Specialist for the Oculovasculogenesis and Angiogenesis Lab at the Wilmer Eye Institute, Johns Hopkins School of Medicine in Baltimore, MD.
Langham OCVM – The Langham family corporation participates in the equity of OcuFLOW, Inc. Fiona Langham is an active principal representing the family. She is an experienced sales and marketing professional and Navy veteran.
The OcuFLOW Composite Ocular Blood Flow Analyzer is a premarket medical device and has not been cleared by the FDA. The information contained herein is for investor and scientific investigational research use only.